Tango Therapeutics TNGX 深 沪
等待开盘 10-31 09:30:00 美东时间
8.03
+0.200
+2.55%
华盛通- 最 高8.175
- 今 开7.83
- 成交量 118.08万股
- 最 低 7.7234
- 昨 收 7.83
- 总市值 8.67亿
- 52周最高 9.70
- 市盈率 静 --
- 换手率 1.09%
- 52周最低 1.03
- 委 比 8.30%
- 总股本 1.08亿
- 历史最高 18.84
- 量 比 0.14
- 振 幅 5.77%
- 历史最低 1.03
- 每 手 1
- 风险率 2.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 升至45美元！英特尔获多家机构上调目标价；大摩上调拖拉机供应公司(TSCO)评级至"标配"，目标价升至60美元
今日重点评级关注：HC Wainwright & Co.：维持Alto Neuroscience"买入"评级，目标价从10美元升至50美元；RBC Capital：维持Precision Drilling"跑赢大市"评级，目标价从110美元升至117美元
10-27 09:45
Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $12
Guggenheim analyst Charles Zhu maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $10 to $12.
10-24 20:01
Tango Therapeutics Announces Major Stock Offering
The latest announcement is out from Tango Therapeutics ( ($TNGX) ). On October ...
10-24 18:48
Tango Therapeutics rises on $225M financing
Tango Therapeutics (NASDAQ:TNGX) has priced an underwritten offering of 21,023,337 shares of common stock and pre-funded warrants to purchase up to 3,226,458 shares. The common stock is priced at $8.6...
10-23 19:33
Tango Therapeutics Announces Preliminary Financial Results
Tango Therapeutics ( ($TNGX) ) has provided an announcement. On October 23, 202...
10-23 19:29
Tango Therapeutics Announces $225M Financing; Prices $210M Offering Of 21M Shares At $8.66 And 3.2M Pre-Funded Warrants At $8.659
Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the pricing of an underwritten
10-23 19:23
Tango Therapeutics' New Drug Doubles Response Rates in Deadly Pancreatic Cancer Trial
Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced positive data from its ongoing
10-23 19:06
Tango Therapeutics Announces $225 Million Financing
<p>Tango Therapeutics, a clinical-stage biotechnology company focused on precision cancer medicines, priced an underwritten offering of 21,023,337 shares of common stock and pre-funded warrants, raising approximately $210 million. The offering price for each share and warrant was $8.66 and $8.659, respectively. The offering is expected to close on October 24, 2025. Notable investors include Farallon Capital Management, TCGX, Balyasny Asset Manage...
10-23 11:20
Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers
Summary: Tango Therapeutics announced positive Phase 1/2 data for vopimetostat in MTAP-deleted cancers, showing 7.2 months mPFS and 25% ORR in 2L pancreatic cancer. Ongoing combination studies with RAS(ON) inhibitors are expected to report data in 2026. The histology-agnostic cohort demonstrated 49% ORR and 9.1 months mPFS. Vopimetostat is well-tolerated with a favorable safety profile, and the company plans to initiate a pivotal trial in 2026.
10-23 11:00
Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025
Tango Therapeutics will present three posters at the SITC 2025 Annual Meeting, highlighting clinical data on TNG260, a novel CoREST inhibitor for non-small cell lung cancer. TNG260 is being tested in combination with pembrolizumab in a Phase 1/2 trial targeting STK11-mutant/RAS wild-type lung cancer patients (~10% of lung adenocarcinoma). The posters will discuss TNG260's safety, efficacy, and its potential to enhance anti-PD-1 therapy in STK11-m...
10-06 11:00
